Data and Safety Monitoring The Data and Safety Monitoring Committee (DSMC) provides rigorous review of all industry and institutional protocols at the HCCC. More specifically, the primary duties of the DSMC are to: ? prospectively screen all patients entering HCCC investigator-initiated trials for trial-specified eligibility. The study coordinator delivers a completed eligibility checklist, with test results, to the safety officer, who verifies that the inclusion and exclusion criteria are met. Questions or concerns about eligibility are discussed with the DSMC chair and/or the Study Monitor. The safety officer then communicates DSMC approval, questions or concerns to the research team before the subject is enrolled in the trial. ? assess safety by reviewing all severe adverse events and ensure timely and appropriate reporting to oversight agencies (e.g. NCI, FDA, IRB) ? conduct audits of selected trials for data veracity, protocol adherence, and subject safety based on overall HCCC Data and Safety Monitoring Plan and the risk level of the study. The DSMC has the authority to close a clinical trial by contacting the IRB should safety issues warrant such closure.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
3P30CA086862-12S1
Application #
8533973
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
2016-03-31
Budget Start
2012-05-03
Budget End
2013-03-31
Support Year
12
Fiscal Year
2012
Total Cost
$2,999
Indirect Cost
$1,013
Name
University of Iowa
Department
Type
DUNS #
062761671
City
Iowa City
State
IA
Country
United States
Zip Code
52242
Meyerholz, David K; Ofori-Amanfo, Georgina K; Leidinger, Mariah R et al. (2017) Immunohistochemical Markers for Prospective Studies in Neurofibromatosis-1 Porcine Models. J Histochem Cytochem 65:607-618
Ebbert, Jon O; Little, Melissa A; Klesges, Robert C et al. (2017) Step Care treatment for smoking cessation. Health Educ Res 32:1-11
Sfeir, J G; Drake, M T; LaPlant, B R et al. (2017) Validation of a vitamin D replacement strategy in vitamin D-insufficient patients with lymphoma or chronic lymphocytic leukemia. Blood Cancer J 7:e526
Mohiuddin, I; Allen, B G (2017) A Single-Institution Experience in Treating Thymic Carcinoma. Int J Radiat Oncol Biol Phys 98:229
Miller, Benjamin J (2017) CORR Insights®: Is It Appropriate to Treat Sarcoma Metastases With Intramedullary Nailing? Clin Orthop Relat Res 475:218-220
Huang, Jianguo; Chen, Mark; Whitley, Melodi Javid et al. (2017) Generation and comparison of CRISPR-Cas9 and Cre-mediated genetically engineered mouse models of sarcoma. Nat Commun 8:15999
Jethava, Yogesh S; Barlogie, Bart; Tricot, Guido J (2017) Drug Combinations with Transplantation for Myeloma. N Engl J Med 377:91-2
Gilbertson-White, Stephanie; Bohr, Nicole; Wickersham, Karen E (2017) Conducting Biobehavioral Research in Patients With Advanced Cancer: Recruitment Challenges and Solutions. Biol Res Nurs 19:481-490
Rogers, Laura M; Mott, Sarah L; Smith, Brian J et al. (2017) Complement-Regulatory Proteins CFHR1 and CFHR3 and Patient Response to Anti-CD20 Monoclonal Antibody Therapy. Clin Cancer Res 23:954-961
Eppsteiner, Robert W; Fowlkes, Jonathan W; Anderson, Carryn M et al. (2017) Aggressive Salivary Malignancies at Early Stage: Outcomes and Implications for Treatment. Ann Otol Rhinol Laryngol 126:525-529

Showing the most recent 10 out of 831 publications